{"entity":{"id":"arjun-balar","kind":"person","name":"Arjun V. Balar","aka":[],"tldr":"Led KEYNOTE-052 and IMvigor210 cohort 1, establishing first-line immunotherapy for cisplatin-ineligible bladder cancer.","summary":"Arjun Balar led KEYNOTE-052 and the cisplatin-ineligible cohort of IMvigor210, the studies that gave pembrolizumab and atezolizumab their first-line approvals in urothelial cancer for patients who cannot receive cisplatin, and KEYNOTE-057 in BCG-unresponsive non-muscle-invasive disease. He continues to lead combination and bladder-preservation trials at NYU.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Balar%20AV%5BAuthor%5D%20urothelial%20pembrolizumab"}],"tags":["urothelial","immunotherapy"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","pdl1"],"drugs":["pembrolizumab","atezolizumab"],"companies":[],"institutions":["nyu-perlmutter"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Director, Genitourinary Medical Oncology Program, NYU Langone Perlmutter Cancer Center","institutionId":"nyu-perlmutter","specialisms":["Urothelial cancer","First-line immunotherapy","Non-muscle-invasive bladder cancer","Combination therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Balar%20AV%5BAuthor%5D%20urothelial%20pembrolizumab"}],"papers":[{"title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052)","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30616-2"},{"title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00147-9"}]},"route":"/people/arjun-balar/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","route":"/institutions/nyu-perlmutter/"}],"trial":[{"id":"keynote-057","kind":"trial","name":"KEYNOTE-057","route":"/trials/keynote-057/"}]}}